此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

口服格列本脲治疗早发性高血糖 (GALOP) (GALOP)

2026年10月1日 更新者:Assistance Publique - Hôpitaux de Paris

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

研究概览

详细说明

Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

研究类型

介入性

注册 (实际的)

35

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Paris、法国、75015
        • Hopital Necker - Enfants malades

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 7个月 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Newborn less than 34 week of amenorrhea corrected age
  • Birth weight < 1500 g
  • Birth term < 32 week of amenorrhea
  • Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
  • Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
  • Enteral feeding considered before inclusion or already established
  • Consent obtained from persons holding parental authority
  • Beneficiary of social security

Exclusion Criteria

  • Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
  • Contraindication to glibenclamide according to current SPC
  • Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
  • Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
  • Severe sepsis requiring mechanical ventilation or haemodynamic support
  • Severe renal dysfunction (serum creatinine > 120 µmol/l)
  • Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
  • Hyperglycemia associated with an error in administering glucose infusion
  • Profound hypophosphoremia (< 1 mmol/l)
  • Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
  • Patient with continuous insulin IV administration
  • Patient treated with miconazole

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Glibenclamide oral

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

  • For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);
  • For subsequent patients included during phase II:
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment
  • 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.
  • In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.

PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution.

blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized

If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.

Transaminases and hemostasis will be done only in case of clinical indication before the first administration.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Blood glucose control
大体时间:At 72 hours after the first administration

The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours)

At 72 hours after the first administration

次要结果测量

结果测量
措施说明
大体时间
Overall success of the treatment
大体时间:At 36 week of amenorrhea corrected age

Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin.

At 36 week of amenorrhea corrected age
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days

Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days

Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
大体时间:At the end of treatment assessed up to 15 days

Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Duration of glibenclamide treatment
大体时间:At the end of treatment assessed up to 15 days

Duration of glibenclamide treatment.

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
大体时间:At the end of treatment assessed up to 15 days

Carbohydrate

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days

lipid

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days

protein

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days

mean caloric intake (kcal/kg/day) during treatment

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
大体时间:At the end of treatment assessed up to 15 days

mean weight gain (g/kg/day)

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
大体时间:At 36 week of amenorrhea corrected age

Carbohydrate

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age

lipid

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age

protein

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age

mean caloric intake (kcal/kg/day) during treatment

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
大体时间:At 36 week of amenorrhea corrected age

mean weight gain ((g/kg/day)

At 36 week of amenorrhea corrected age
Number of children with episode of hypoglycemia
大体时间:At 72 hours after first administration

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At 72 hours after first administration
Number of children with episode of hypoglycemia
大体时间:At the end of treatment assessed up to 15 days

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At the end of treatment assessed up to 15 days
Type of adverse reactions on glibenclamide
大体时间:At 36 week of amenorrhea corrected age

evaluation of the type of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of adverse reactions on glibenclamide
大体时间:At 36 week of amenorrhea corrected age

evaluation of number of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of participants with co-morbidity
大体时间:At 36 week of amenorrhea corrected age

Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis

At 36 week of amenorrhea corrected age
Mortality
大体时间:At 36 week of amenorrhea corrected age

Mortality will be assessed

At 36 week of amenorrhea corrected age
Dose adjustment
大体时间:At the end of treatment assessed up to 15 days

Number of dose adjustments, to evaluate the easy of use

At the end of treatment assessed up to 15 days
ease of use by caregivers
大体时间:At day one of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day one of treatment
ease of use by caregivers
大体时间:At day two of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day two of treatment
ease of use by caregivers
大体时间:At day three of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day three of treatment
Plasma concentrations of glibenclamide
大体时间:At 3 hours after the first administration

Evaluated by the pharmacokinetics study

At 3 hours after the first administration
Plasma concentrations of glibenclamide
大体时间:At 6 hours after the first administration

Evaluated by the pharmacokinetics study

At 6 hours after the first administration
Plasma concentrations of glibenclamide
大体时间:At 10 hours after the first administration

Evaluated by the pharmacokinetics study

At 10 hours after the first administration
Plasma concentrations of glibenclamide
大体时间:At 24 hours after the first administration

Evaluated by the pharmacokinetics study

At 24 hours after the first administration
Plasma concentrations of glibenclamide
大体时间:At 24 hours of blood glucose stabilization

Evaluated by the pharmacokinetics study

At 24 hours of blood glucose stabilization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Jacques BELTRAND, Pr、Assistance Publique - Hôpitaux de Paris
  • 研究主任:Michel POLAK、Assistance Publique - Hôpitaux de Paris
  • 研究主任:Delphine MITANCHEZ、CHRU de Tours

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年5月20日

初级完成 (实际的)

2025年10月30日

研究完成 (实际的)

2026年1月8日

研究注册日期

首次提交

2022年12月7日

首先提交符合 QC 标准的

2023年1月6日

首次发布 (实际的)

2023年1月18日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅